The company reported in a release that among 157 people with stage 3 or stage 4 melanoma, a personalized cancer vaccine that Moderna developed with Merck—created using mRNA genetic material from each patient’s respective tumors—reduced the risk of recurrence or death by 44% compared to standard care.New COVID-19 shots with different viral targets were created and manufactured in about six weeks by both Moderna and Pfizer-BioNTech, makers of another mRNA COVID-19 vaccine.It also took about six weeks for Moderna’s scientists to generate each personalized mRNA cancer vaccine.- FTX Founder Sam Bankman-Fried Charged With Fraud by SEC After Arrest in the Bahamas- How 2022 Became the Year of Gossip- Column: Amid Musk's Chaotic Reign at Twitter, Our Digital History Is at Risk- Mars May Have Active Volcanoes, Adding New Promise to Search for Extraterrestrial Life- The 10 Moments That Defined Fashion in 2022- Why We Say 'Merry Christmas.'The Surprising Origins of 5 Christmas Traditions- Column: It’s Going to Be a Grim Winter for Ukraine- Everything We Learned From the Meghan Markle and Prince Harry Netflix Docuseries- Volodymyr Zelensky and the Spirit of Ukraine: TIME's 2022 Person of the Year"